AMRN Amarin Corporation plc - American Depositary Shares
$14.37
Price · Aug 19, 2026
Fundamentals as of Jul 29, 2026
52W Range
$13–$21
18% of range
Analyst Rating
HOLD
6 analysts
Price Target
$12
P/E (TTM)
-159.7
ROE
-8.4%
Net Profit Margin
-18.2%
About Amarin Corporation plc - American Depositary Shares Company overview from Wikipedia
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
Read more
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
In July 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval, competing against GlaxoSmithKline's Lovaza.
History
Amarin Corporation plc (formerly Ethical Holdings plc) was originally incorporated in England as a private limited company on March 1, 1989, and later re-registered as a public company on March 19, 1993. In 2002, the company suffered losses worth $37 million; 2003 losses exceeded $19 million. As of 2005, it was developing neurology drugs. It developed Miraxion to treat serious hereditary neurodegenerative disease.
In December 2007, Amarin acquired Ester Neurosciences Limited for US$8.1 million. In 2011, CEO Joe Zakrzewski said that the company would like to first work on building its infrastructure out to commercialize the drug in the United States.
Products and development
Vascepa (USA) / Vazkepa (EU)
Amarin´s sole product VASCEPA® came on the market in 2013 for triglyceride levels >=500 milligrams per deciliter. In December 2019, the FDA approved "...the use of Vascepa (icosapent ethyl) as an adjunctive (secondary) therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels (a type of fat in the blood) of 150 milligrams per deciliter or higher. Patients must also have either established cardiovascular disease or diabetes and two or more additional risk factors for cardiovascular disease....Vascepa is the first FDA approved drug to reduce cardiovascular risk among patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy.
Furthermore, VASCEPA® is in use in clinical trials by 3rd parties to see, if it has an effect on Alzheimer, Colon Cancer, Nonalcoholic Steatohepatitis (NASH), and other diseases.
HLS Therapeutics, Amarin´s license partner in Canada, presented results of their COVID-19 clinical trial for Vascepa at National Lipid Association Scientific Sessions 2020, December 12. The results demonstrated a 25% reduction of hs-CRP, a biomarker for inflammation. Most people with COVID-19 die, because of a cytokine storm, which causes an uncontrolled and excessive release of pro-inflammatory signaling molecules called cytokines. Two more COVID-19 studies are actually running with Vascepa to validate and proof further benefits.
On January 28, the Committee for Medicinal Products for Human Use gave a positive recommendation for Vazcepa (its name in the EU), which the European Commission finally approved on March 30.
Patent disputes
On March 30, 2020, the designated patent judge in the U.S. District Court for the District of Nevada, Miranda Du, ruled for generic-drug makers Hikma Pharmaceuticals and Dr. Reddy's Laboratories in a lawsuit with Amarin over patents on Amarin's drug, Vascepa. Soon after, on April 2, 2020, Amarin filed an appeal of the ruling. The appeal was lost and an en-banc was also not granted, afterwards. On November 30, three weeks after Hikma Pharmaceuticals started the distribution of their generic version of Vascepa, Amarin filed a complaint of patent infringement against Hikma. On February 11, 2021, Amarin filed a petition for certiorari with the US Supreme Court. On June 21, 2021, the petition was denied.
== Finance ==
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
AMRN Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$14.37
Market Cap
$5.98B
P/E (TTM)
-159.7
EPS (TTM)
$-0.09
Revenue (TTM)
$214M
Div Yield
—
ROE
-8.4%
Debt/Equity
—
52W Range
$13 – $21
AMRN Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
$214M
2016-12-31
→
2025-12-31
EPS
$-0.09
2016-12-31
→
2025-12-31
Free Cash Flow
—
2016-12-31
→
2020-12-31
Margins
-18.2%
2016-12-31
→
2025-12-31
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
AMRN
Peer Median
P/E (TTM)
-159.7
55.9
P/S (TTM)
28.0
5.5
P/B
13.0
1.8
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
AMRN
Peer Median
Gross Margin
56.6%
63.8%
Operating Margin
-23.5%
—
Net Profit Margin
-18.2%
-14.2%
ROA
-5.7%
-4.2%
ROE
-8.4%
-6.0%
ROIC
-11.8%
—
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
AMRN
Peer Median
Current Ratio
3.3
3.7
Quick Ratio
2.2
—
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
AMRN
Peer Median
Revenue YoY
-6.6%
—
Revenue CAGR 3Y
-16.7%
—
Revenue CAGR 5Y
-19.0%
—
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
AMRN
Peer Median
AMRN Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
SELL
6 analysts
- Strong Buy 0 0.0%
- Buy 0 0.0%
- Hold 2 33.3%
- Sell 2 33.3%
- Strong Sell 2 33.3%
12-Month Price Target
1 analysts · 2026-08-15
Low
$12.00
High
$12.00
Median target
$12.00
-16.5%
Mean target
$12.00
-16.5%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
0.20%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| June 30, 2026 | $0.04 | $-0.01 | 0.05% |
| March 31, 2026 | $-0.09 | $0.09 | -0.18% |
| Dec. 31, 2025 | $0.01 | $0.00 | 0.01% |
| Sept. 30, 2025 | $0.08 | $-0.58 | 0.66% |
| June 30, 2025 | $0.66 | $-0.18 | 0.84% |
| March 31, 2025 | $-0.76 | $-0.58 | -0.18% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| AMRN | $5.81B | -155.1 | -6.6% | -18.2% | -8.4% | 56.6% |
| ALKS | $4.63B | 19.6 | -5.2% | 16.4% | 14.0% | — |
| PRTA | $514M | -2.1 | -92.8% | -2520.6% | -63.6% | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 18
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $214M | $229M | $307M | $369M | $583M | $614M | $430M | $229M | $181M | $130M | $82M | $54M | |
| Cost of Revenue | · | · | · | · | $121M | $131M | $96M | $55M | $45M | $34M | $28M | $20M | |
| Gross Profit | $121M | $81M | $166M | $242M | $462M | $483M | $334M | $175M | $136M | $96M | $54M | $34M | |
| R&D Expense | $20M | $21M | $22M | $30M | $29M | $39M | $34M | $56M | $47M | $50M | $51M | $50M | |
| SG&A Expense | $115M | $152M | $200M | $304M | $408M | $463M | $324M | $227M | $135M | $111M | $101M | $79M | |
| Operating Expenses | $171M | $173M | $233M | $348M | $451M | $502M | $358M | $283M | $182M | $161M | $152M | $130M | |
| Operating Income | $-50M | $-92M | $-68M | $-106M | $11M | $-20M | $-24M | $-108M | $-46M | $-66M | $-98M | $-96M | |
| Interest Expense | $7.0K | $7.0K | $8.0K | $15.0K | $129.0K | $3M | $7M | $9M | $10M | $19M | $20M | $19M | |
| Interest Income | $11M | $13M | $12M | $3M | $1M | $5M | $8M | $1M | $429.0K | $234.0K | $132.0K | $96.0K | |
| Other Non-op | $3M | $1M | $2M | $-740.0K | $-302.0K | $104.0K | $-75.0K | $-326.0K | $74.0K | $-482.0K | $-228.0K | $4M | |
| Pretax Income | $-36M | $-77M | $-54M | $-104M | $11M | $-17M | $-22M | $-116M | $-55M | $-76M | $-118M | $-59M | |
| Income Tax | $3M | $5M | $5M | $2M | $4M | $745.0K | $164.0K | $96.0K | $13M | $10M | $-3M | $-3M | |
| Net Income | $-39M | $-82M | $-59M | $-106M | $8M | $-18M | $-23M | $-116M | $-68M | $-86M | $-115M | $-56M | |
| EPS (Basic) | $-0.09 | $-0.20 | $-0.15 | $-0.26 | $0.02 | $-0.05 | $-0.07 | $-0.39 | $-0.25 | $-0.41 | $-0.83 | $-0.32 | |
| EPS (Diluted) | $-0.09 | $-0.20 | $-0.15 | $-0.26 | $0.02 | $-0.05 | $-0.07 | $-0.39 | $-0.25 | $-0.41 | $-0.83 | $-0.36 | |
| Shares (Basic) | 414,984,000 | 410,937,000 | 407,655,000 | 401,155,000 | 395,992,000 | 381,759,000 | 342,538,000 | 297,237,000 | 270,652,000 | 211,874,000 | 180,654,000 | 173,719,000 | |
| Shares (Diluted) | 414,984,000 | 410,937,000 | 407,655,000 | 401,155,000 | 402,480,000 | 381,759,000 | 342,538,000 | 297,237,000 | 270,652,000 | 211,874,000 | 180,654,000 | 173,824,000 | |
| EBITDA | $-50M | $-92M | $-68M | · | · | $-20M | · | $-108M | $-46M | $-66M | $-98M | $-96M |
Balance Sheet 27
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $135M | $121M | $199M | $218M | $219M | $187M | $645M | $249M | $74M | $98M | $107M | $120M | |
| Short-term Investments | $168M | $173M | $121M | $92M | $235M | $314M | · | · | · | · | · | · | |
| Receivables | $127M | $122M | $134M | $131M | $164M | $155M | $116M | $67M | $45M | $20M | $14M | $8M | |
| Inventory | $196M | $166M | $259M | $229M | $235M | $189M | $77M | $58M | $30M | $21M | $19M | $14M | |
| Prepaid Expense | $24M | $13M | $12M | $19M | $22M | $31M | $13M | $3M | $3M | $7M | $3M | $3M | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $3M | |
| Current Assets | $650M | $595M | $725M | $689M | $879M | $879M | $855M | $378M | $153M | $146M | $144M | $145M | |
| PP&E (Net) | $12.0K | $16.0K | $114.0K | $874.0K | $1M | $2M | $2M | $63.0K | $28.0K | $78.0K | $243.0K | $381.0K | |
| PP&E (Gross) | $1M | $1M | $1M | $3M | $3M | $4M | $3M | $902.0K | $844.0K | $821.0K | $997.0K | $969.0K | |
| Accum. Depreciation | $1M | $1M | $1M | $2M | $2M | $2M | $1M | $839.0K | $816.0K | $755.0K | $754.0K | $588.0K | |
| Intangibles | $13M | $16M | $19M | $22M | $24M | $14M | $15M | $7M | $8M | $9M | $9M | $10M | |
| Other Non-current Assets | $1M | $1M | $1M | $458.0K | $456.0K | $432.0K | $1M | $174.0K | $174.0K | $741.0K | $174.0K | $3M | |
| Total Assets | $671M | $685M | $832M | $886M | $1.07B | $966M | $882M | $386M | $162M | $167M | $173M | $171M | |
| Accounts Payable | $45M | $40M | $53M | $65M | $115M | $106M | $50M | $38M | $25M | $6M | $11M | $9M | |
| Current Liabilities | $194M | $180M | $259M | $259M | $371M | $307M | $242M | $157M | $109M | $76M | $51M | $40M | |
| Capital Leases | $6M | $8M | $9M | $10M | $9M | $9M | $9M | · | · | · | · | · | |
| Other Non-current Liabilities | $11M | $12M | $9M | $8M | $8M | $6M | $4M | $11M | $1M | $710.0K | $335.0K | $386.0K | |
| Total Liabilities | $211M | $199M | $280M | $291M | $401M | $339M | $274M | $233M | $227M | $176M | $301M | $260M | |
| Long-term Debt | · | · | · | · | · | · | $50M | $80M | $92M | $94M | $92M | $105M | |
| Total Debt | · | · | · | · | · | $0 | · | $80M | $93M | $101M | $106M | $105M | |
| Common Stock | $310M | $305M | $303M | $299M | $294M | $290M | $269M | $247M | $209M | $207M | $150M | $143M | |
| Paid-in Capital | $1.92B | $1.91B | $1.90B | $1.89B | $1.86B | $1.82B | $1.76B | $1.28B | $978M | · | · | · | |
| Retained Earnings | $-1.71B | $-1.67B | $-1.59B | $-1.53B | $-1.42B | $-1.43B | $-1.41B | $-1.39B | $-1.27B | $-1.20B | $-1.12B | $-970M | |
| Treasury Stock | $67M | $65M | $64M | $62M | $61M | $51M | $36M | $10M | $4M | $1M | $411.0K | $217.0K | |
| Stockholders' Equity | $459M | $486M | $552M | $595M | $667M | $628M | $608M | $152M | $-65M | $-9M | $-129M | $-88M | |
| Liabilities + Equity | $671M | $685M | $832M | $886M | $1.07B | $966M | $882M | $386M | $162M | $167M | $173M | $171M | |
| Shares Outstanding | 416,214,102 | 411,584,851 | 408,824,093 | 408,824,093 | 396,598,008 | 392,538,081 | 360,103,901 | 325,850,013 | 271,022,011 | 269,363,696 | 183,403,263 | 174,590,372 |
Cash Flow 17
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $23.0K | $62.0K | $138.0K | $166.0K | $198.0K | |
| Stock-based Comp | $14M | $18M | $16M | $26M | $37M | $46M | $31M | $19M | $14M | $14M | $14M | $9M | |
| Deferred Tax | · | · | · | · | · | · | · | · | $11M | $9M | $-4M | $-4M | |
| Amort. of Intangibles | $3M | $3M | $3M | $3M | $2M | $1M | $679.0K | $646.0K | $646.0K | $645.0K | $646.0K | $646.0K | |
| Restructuring | $36M | $0 | $11M | $14M | $14M | · | · | · | · | · | · | · | |
| Operating Cash Flow | $7M | $-31M | $7M | $-180M | $-67M | $-22M | $-9M | $-95M | $-33M | $-72M | $-84M | $-75M | |
| CapEx | · | · | · | · | · | $252.0K | $2M | $58.0K | $12.0K | $21.0K | $28.0K | · | |
| Investing Cash Flow | $9M | $-46M | $-26M | $175M | $104M | $-377M | $-2M | $-58.0K | $-12.0K | $-21.0K | · | · | |
| Net Debt Issued | · | · | · | · | · | $-50M | · | $-15M | $-3M | · | · | · | |
| Stock Issued | · | · | · | · | · | · | $440M | $265M | · | $65M | · | · | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | $194.0K | · | |
| Net Stock Activity | · | · | · | · | · | · | · | $265M | · | $65M | $-194.0K | · | |
| Financing Cash Flow | $-2M | $-1M | $230.0K | $-379.0K | $-5M | $-59M | $410M | $271M | $8M | $63M | · | · | |
| Net Change in Cash | $14M | $-78M | $-18M | $-5M | $32M | $-458M | $398M | $176M | $-25M | $-9M | $-13M | $-72M | |
| Taxes Paid | $1M | $4M | $2M | $-2M | $4M | $-207.0K | $-67.0K | · | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | $-22M | · | $-95M | $-33M | $-72M | $-85M | · | |
| Levered FCF | · | · | · | · | · | $-25M | · | $-104M | $-45M | $-93M | $-104M | · |
Profitability 8
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.6% | 35.6% | 53.9% | · | · | 78.6% | · | 76.2% | 75.2% | 73.6% | 65.9% | 62.2% | |
| Operating Margin | -23.5% | -40.2% | -22.0% | · | · | -3.2% | · | -47.2% | -25.1% | -50.4% | -120.1% | -177.0% | |
| Net Margin | -18.2% | -35.9% | -19.3% | · | · | -2.9% | · | -50.8% | -37.5% | -66.4% | -140.9% | -104.0% | |
| Pretax Margin | -16.9% | -33.8% | -17.5% | · | · | -2.8% | · | -50.8% | -30.3% | -58.7% | -144.7% | -109.2% | |
| EBITDA Margin | -23.5% | -40.2% | -22.0% | · | · | -3.2% | · | -47.2% | -25.1% | -50.4% | -120.1% | -177.0% | |
| ROA | -5.7% | -10.8% | -6.9% | · | · | -1.9% | · | -42.5% | -41.3% | -50.8% | -66.9% | -26.6% | |
| ROE | -8.4% | -16.2% | -10.7% | · | · | -2.9% | · | -234.1% | 183.0% | 124.9% | 105.9% | 92.2% | |
| ROIC | -11.8% | -20.1% | -13.5% | · | · | -3.3% | · | -46.6% | -200.8% | -80.6% | 417.0% | -551.6% |
Liquidity & Solvency 5
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.3 | 2.8 | · | · | 2.9 | · | 2.4 | 1.4 | 1.9 | 2.8 | 3.6 | |
| Quick Ratio | 2.2 | 2.3 | 1.8 | · | · | 2.1 | · | 2.0 | 1.1 | 1.6 | 2.4 | 3.2 | |
| Debt / Equity | · | · | · | · | · | 0.0 | · | 0.5 | -1.4 | -11.2 | -0.8 | -1.2 | |
| LT Debt / Equity | · | · | · | · | · | · | · | 0.3 | -1.1 | -9.4 | -0.7 | -1.0 | |
| Interest Coverage | -7167.1 | -13113.9 | -8448.5 | · | · | -7.5 | · | -12.2 | -4.7 | -3.5 | -4.9 | -5.2 |
Efficiency 3
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | 0.4 | · | · | 0.7 | · | 0.8 | 1.1 | 0.8 | 0.5 | 0.3 | |
| Inventory Turnover | · | · | · | · | · | 1.0 | · | 1.2 | 1.8 | 1.7 | 1.7 | 1.2 | |
| Receivables Turnover | 1.7 | 1.8 | 2.3 | · | · | 4.5 | · | 4.1 | 5.5 | 7.7 | 7.5 | 9.4 |
Growth Rates 3
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -6.6% | -25.5% | -16.9% | -36.7% | -5.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -16.7% | -26.8% | -20.6% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -19.0% | · | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM) 14
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $214M | $229M | $307M | $369M | $583M | $614M | $430M | $229M | $181M | $130M | $82M | $54M | |
| Net Income TTM | $-39M | $-82M | $-59M | $-106M | $8M | $-18M | $-23M | $-116M | $-68M | $-86M | $-115M | $-56M | |
| Market Cap | $5.81B | $4.03B | $7.11B | · | · | $38.39B | · | $88.70B | $21.74B | $16.59B | $6.93B | $3.42B | |
| Enterprise Value | · | · | · | · | · | $37.89B | · | $88.53B | $21.76B | $16.60B | $6.93B | $3.41B | |
| P/E | -155.1 | -49.0 | -116.0 | -93.1 | 3370.0 | -1956.0 | -6125.7 | -697.9 | -320.8 | -150.2 | -45.5 | -54.4 | |
| P/S | 27.2 | 17.6 | 23.2 | · | · | 62.5 | · | 387.0 | 120.0 | 127.6 | 84.8 | 63.1 | |
| P/B | 12.7 | 8.3 | 12.9 | · | · | 61.2 | · | 582.3 | -333.9 | -1831.8 | -53.7 | -38.7 | |
| P / Tangible Book | 13.0 | 8.6 | 13.4 | 17.1 | 41.5 | 62.6 | · | · | · | · | · | · | |
| P / Cash Flow | 863.6 | -130.0 | 1033.9 | · | · | -1765.4 | · | -936.6 | -661.9 | -231.0 | -81.8 | -47.3 | |
| P / FCF | · | · | · | · | · | -1745.2 | · | -936.0 | -661.7 | -231.0 | -81.8 | · | |
| EV / EBITDA | · | · | · | · | · | -1927.7 | · | -818.0 | -477.6 | -252.9 | -70.6 | -35.5 | |
| EV / FCF | · | · | · | · | · | -1722.4 | · | -934.2 | -662.3 | -231.0 | -81.8 | · | |
| EV / Revenue | · | · | · | · | · | 61.7 | · | 386.2 | 120.1 | 127.6 | 84.8 | 62.9 | |
| Earnings Yield | -0.64% | -2.0% | -0.86% | -1.1% | 0.03% | -0.05% | -0.02% | -0.14% | -0.31% | -0.67% | -2.2% | -1.8% |
Income Statement 16
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $42M | $45M | $49M | $50M | $73M | $42M | $62M | $42M | $67M | $57M | $75M | $66M | $80M | $86M | $90M | $90M | |
| Gross Profit | $15M | $18M | $23M | $22M | $50M | $25M | $-10M | $16M | $43M | $32M | $45M | $30M | $43M | $48M | $64M | $63M | |
| R&D Expense | $5M | $5M | $5M | $4M | $5M | $5M | $6M | $5M | $5M | $6M | $6M | $5M | $6M | $6M | $5M | $6M | |
| SG&A Expense | $22M | $21M | $20M | $20M | $39M | $37M | $37M | $37M | $39M | $40M | $44M | $45M | $51M | $60M | $68M | $59M | |
| Operating Expenses | $27M | $29M | $29M | $33M | $66M | $42M | $43M | $41M | $43M | $45M | $50M | $51M | $67M | $65M | $73M | $68M | |
| Operating Income | $-12M | $-11M | $-6M | $-11M | $-16M | $-17M | $-53M | $-25M | $-524.0K | $-14M | $-5M | $-21M | $-24M | $-17M | $-10M | $-5M | |
| Interest Income | $3M | $2M | · | · | $3M | $3M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-op | $1M | $188.0K | $3M | $205.0K | $-85.0K | $253.0K | $-754.0K | $265.0K | $145.0K | $2M | $-1M | $-575.0K | $3M | $624.0K | $1M | $511.0K | |
| Pretax Income | $-8M | $-9M | $-853.0K | $-8M | $-13M | $-14M | $-50M | $-22M | $3M | $-9M | $-2M | $-19M | $-18M | $-14M | $-7M | $-4M | |
| Income Tax | $-219.0K | $2M | $371.0K | $-377.0K | $689.0K | $2M | $-1M | $4M | $1M | $1M | $3M | $501.0K | $-355.0K | $2M | $-8M | $1M | |
| Net Income | $-8M | $-11M | $-1M | $-8M | $-14M | $-16M | $-49M | $-25M | $2M | $-10M | $-6M | $-19M | $-18M | $-16M | $856.0K | $-5M | |
| EPS (Basic) | $-0.02 | $-0.03 | $0.00 | $-0.02 | $-0.03 | $-0.04 | $-0.12 | $-0.06 | $0.00 | $-0.02 | $-0.02 | $-0.05 | $-0.04 | $-0.04 | $0.01 | $-0.01 | |
| EPS (Diluted) | $-0.02 | $-0.03 | $0.00 | $-0.02 | $-0.03 | $-0.04 | $-0.12 | $-0.06 | $0.00 | $-0.02 | $-0.02 | $-0.05 | $-0.04 | $-0.04 | $0.01 | $-0.01 | |
| Shares (Basic) | 416,444,000 | 419,054,000 | -828,446,000 | 415,531,000 | 414,477,000 | 413,422,000 | -821,210,000 | 411,150,000 | 410,851,000 | 410,146,000 | -814,787,000 | 408,417,000 | 407,848,000 | 406,177,000 | -799,451,000 | 404,614,000 | |
| Shares (Diluted) | 416,444,000 | 419,054,000 | -828,446,000 | 415,531,000 | 414,477,000 | 413,422,000 | -821,754,000 | 411,150,000 | 411,395,000 | 410,146,000 | -814,787,000 | 408,417,000 | 407,848,000 | 406,177,000 | -799,451,000 | 404,614,000 | |
| EBITDA | $-12M | $-11M | · | $-11M | $-16M | $-17M | · | $-25M | $-524.0K | $-14M | · | $-21M | $-24M | $-17M | · | $-5M |
Balance Sheet 24
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $144M | $131M | $135M | $123M | $148M | $120M | $121M | $157M | $216M | $214M | · | $271M | $233M | $191M | · | $240M | |
| Short-term Investments | $171M | $177M | $168M | $164M | $151M | $162M | $173M | $149M | $91M | $94M | · | $50M | $80M | $113M | · | $63M | |
| Receivables | $93M | $108M | $127M | $127M | $119M | $107M | $122M | $113M | $124M | $116M | · | $122M | $123M | $133M | · | $123M | |
| Inventory | $164M | $184M | $196M | $185M | $171M | $159M | $166M | $224M | $239M | $255M | · | $254M | $227M | $226M | · | $228M | |
| Prepaid Expense | $31M | $26M | $24M | $29M | $17M | $25M | $13M | $7M | $32M | $8M | · | $19M | $43M | $20M | · | $28M | |
| Current Assets | $603M | $626M | $650M | $628M | $607M | $573M | $595M | $650M | $702M | $688M | · | $718M | $706M | $684M | · | $687M | |
| PP&E (Net) | · | · | $12.0K | $13.0K | $14.0K | $15.0K | $16.0K | $24.0K | $49.0K | $81.0K | · | $147.0K | $179.0K | $187.0K | · | $999.0K | |
| PP&E (Gross) | · | · | $1M | · | · | · | $1M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $1M | · | · | · | $1M | · | · | · | · | · | · | · | · | · | |
| Intangibles | $12M | $13M | $13M | $14M | $15M | $16M | $16M | $17M | $18M | $19M | · | $20M | $20M | $21M | · | $22M | |
| Other Non-current Assets | $4M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | · | $1M | $2M | $2M | · | $456.0K | |
| Total Assets | $624M | $646M | $671M | $660M | $670M | $656M | $685M | $751M | $800M | $790M | · | $839M | $860M | $860M | · | $908M | |
| Accounts Payable | $19M | $48M | $45M | $37M | $45M | $46M | $40M | $41M | $54M | $68M | · | $53M | $54M | $59M | · | $93M | |
| Current Liabilities | $164M | $180M | $194M | $182M | $186M | $162M | $180M | $202M | $231M | $224M | · | $267M | $271M | $244M | · | $287M | |
| Capital Leases | $5M | $6M | $6M | $7M | $7M | $8M | $8M | $8M | $8M | $8M | · | $9M | $9M | $10M | · | $10M | |
| Other Non-current Liabilities | $11M | $11M | $11M | $12M | $12M | $12M | $12M | $9M | $9M | $9M | · | $7M | $7M | $9M | · | $10M | |
| Total Liabilities | $181M | $196M | $211M | $201M | $205M | $182M | $199M | $219M | $248M | $244M | · | $286M | $291M | $275M | · | $320M | |
| Common Stock | $315M | $314M | $310M | $310M | $309M | $308M | $305M | $305M | $305M | $305M | · | $302M | $302M | $301M | · | $299M | |
| Paid-in Capital | $1.92B | $1.92B | $1.92B | $1.92B | $1.92B | $1.92B | $1.91B | $1.91B | $1.91B | $1.90B | · | $1.90B | $1.89B | $1.89B | · | $1.88B | |
| Retained Earnings | $-1.73B | $-1.72B | $-1.71B | $-1.71B | $-1.70B | $-1.68B | $-1.67B | $-1.62B | $-1.59B | $-1.60B | · | $-1.58B | $-1.56B | $-1.54B | · | $-1.53B | |
| Treasury Stock | $69M | $69M | $67M | $67M | $67M | $66M | $65M | $65M | $65M | $65M | · | $64M | $63M | $63M | · | $62M | |
| Stockholders' Equity | $444M | $449M | $459M | $459M | $465M | $474M | $486M | $531M | $552M | $546M | $552M | $553M | $569M | $585M | $595M | $588M | |
| Liabilities + Equity | $624M | $646M | $671M | $660M | $670M | $656M | $685M | $751M | $800M | $790M | · | $839M | $860M | $860M | · | $908M | |
| Shares Outstanding | 420,044,022 | 419,594,602 | 416,214,102 | 415,965,977 | 415,401,497 | 414,365,189 | 411,584,851 | 411,261,678 | 411,113,770 | 410,735,780 | · | 408,551,020 | 408,133,807 | 407,265,944 | 408,824,093 | 403,828,955 |
Cash Flow 9
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $2M | $2M | $6M | $4M | $3M | $5M | $4M | $5M | $5M | $4M | $2M | $6M | $7M | $5M | |
| Amort. of Intangibles | $636.0K | $637.0K | $701.0K | $866.0K | $728.0K | $729.0K | $729.0K | $728.0K | $729.0K | $729.0K | $701.0K | $701.0K | $701.0K | $702.0K | $636.0K | $636.0K | |
| Restructuring | $40.0K | $3M | $4M | $9M | $23M | · | · | · | · | · | $229.0K | $711.0K | $10M | · | $-180.0K | $3M | |
| Operating Cash Flow | $7M | $6M | $15M | $-13M | $17M | $-12M | $-13M | $-2M | $-3M | $-13M | $-645.0K | $7M | $7M | $-7M | $2M | $-18M | |
| Investing Cash Flow | $6M | $-8M | $-4M | $-12M | $12M | $12M | $-23M | $-57M | $5M | $29M | $-71M | $31M | $34M | $-20M | $-28M | $31M | |
| Stock Issued | · | · | · | · | · | · | · | $0 | · | · | · | $0 | · | · | · | $0 | |
| Financing Cash Flow | $-247.0K | $-2M | $-4.0K | $-248.0K | $-663.0K | $-1M | $17.0K | $-68.0K | $34.0K | $-1M | $83.0K | $-277.0K | $60.0K | $364.0K | $38.0K | $-156.0K | |
| Net Change in Cash | $12M | $-4M | $12M | $-25M | $28M | $-2M | $-36M | $-59M | $2M | $15M | $-72M | $38M | $42M | $-26M | $-26M | $12M | |
| Taxes Paid | $1M | $2M | $1M | $-1.0K | $-169.0K | $22.0K | $6M | $-1M | $-698.0K | $29.0K | $3M | $-432.0K | $-633.0K | $38.0K | $-292.0K | $622.0K |
Profitability 8
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 35.5% | 39.4% | · | 44.7% | 69.2% | 59.8% | · | 38.5% | 63.4% | 56.5% | · | 45.1% | 53.2% | 55.8% | · | 69.9% | |
| Operating Margin | -28.4% | -25.1% | · | -22.4% | -22.0% | -39.9% | · | -59.5% | -0.78% | -24.0% | · | -32.5% | -29.9% | -20.2% | · | -5.7% | |
| Net Margin | -18.1% | -23.3% | · | -15.6% | -19.4% | -37.4% | · | -59.4% | 2.3% | -17.6% | · | -29.2% | -21.9% | -19.1% | · | -5.7% | |
| Pretax Margin | -18.6% | -19.3% | · | -16.3% | -18.5% | -32.4% | · | -50.9% | 4.3% | -15.3% | · | -28.5% | -22.4% | -16.9% | · | -4.3% | |
| EBITDA Margin | -28.4% | -25.1% | · | -22.4% | -22.0% | -39.9% | · | -59.5% | -0.78% | -24.0% | · | -32.5% | -29.9% | -20.2% | · | -5.7% | |
| ROA | -1.2% | -1.6% | · | -1.1% | -1.9% | -2.2% | · | -3.2% | 0.18% | -1.2% | · | -2.2% | -1.9% | -1.8% | · | -0.53% | |
| ROE | -1.7% | -2.3% | · | -1.6% | -2.8% | -3.1% | · | -4.6% | 0.27% | -1.8% | · | -3.4% | -3.1% | -2.7% | · | -0.84% | |
| ROIC | -2.6% | -3.0% | · | -2.3% | -3.6% | -4.1% | · | -5.5% | -0.05% | -2.9% | · | -4.0% | -4.1% | -3.4% | · | -1.2% |
Liquidity & Solvency 2
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | 3.5 | · | 3.4 | 3.3 | 3.5 | · | 3.2 | 3.0 | 3.1 | · | 2.7 | 2.6 | 2.8 | · | 2.4 | |
| Quick Ratio | 2.5 | 2.3 | · | 2.3 | 2.2 | 2.4 | · | 2.1 | 1.9 | 1.9 | · | 1.7 | 1.6 | 1.8 | · | 1.5 |
Efficiency 2
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 0.4 | 0.4 | · | 0.4 | 0.6 | 0.4 | · | 0.4 | 0.5 | 0.5 | · | 0.5 | 0.6 | 0.7 | · | 0.7 |
Valuation (TTM) 9
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $210M | $210M | · | $207M | $225M | $208M | · | $232M | $270M | $289M | · | $322M | $350M | $365M | · | $421M | |
| Net Income TTM | $-40M | $-48M | · | $-63M | $-53M | $-49M | · | $-53M | $-45M | $-63M | · | $-58M | $-109M | $-123M | · | $-120M | |
| Market Cap | $6.70B | $6.07B | · | $6.81B | $6.74B | $3.73B | · | $5.18B | $5.67B | $7.31B | · | $7.52B | $9.71B | $12.22B | · | $8.80B | |
| P/E | -159.4 | -120.5 | · | -109.2 | -124.8 | -75.0 | · | -96.9 | -125.5 | -118.7 | · | -131.4 | -88.1 | -96.8 | · | -72.7 | |
| P/S | 31.9 | 29.0 | · | 33.0 | 30.0 | 17.9 | · | 22.3 | 21.0 | 25.3 | · | 23.3 | 27.7 | 33.5 | · | 20.9 | |
| P/B | 15.1 | 13.5 | · | 14.8 | 14.5 | 7.9 | · | 9.8 | 10.3 | 13.4 | · | 13.6 | 17.1 | 20.9 | · | 15.0 | |
| P / Tangible Book | 15.5 | 13.9 | · | 15.3 | 15.0 | 8.1 | · | 10.1 | 10.6 | 13.9 | · | 14.1 | 17.7 | 21.7 | · | 15.5 | |
| P / Cash Flow | · | 949.8 | · | · | · | -299.3 | · | · | · | -580.2 | · | · | · | -1743.4 | · | · | |
| Earnings Yield | -0.63% | -0.83% | · | -0.92% | -0.80% | -1.3% | · | -1.0% | -0.80% | -0.84% | · | -0.76% | -1.1% | -1.0% | · | -1.4% |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Income Statement
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Revenue | $214M | $229M | $307M | $369M | $583M |
| Gross Margin % | 56.6% | 35.6% | 53.9% | — | — |
| Operating Margin % | -23.5% | -40.2% | -22.0% | — | — |
| Net Income | $-39M | $-82M | $-59M | $-106M | $8M |
| Diluted EPS | $-0.09 | $-0.20 | $-0.15 | $-0.26 | $0.02 |
Balance Sheet
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.3 | 2.8 | — | — |
| Quick Ratio | 2.2 | 2.3 | 1.8 | — | — |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 90 filers · $59.1M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 23 (+15 vs prior Q) | 7 (-12 vs prior Q) | 19 (+1 vs prior Q) | 10 (-3 vs prior Q) | +89K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| Sarissa Capital Management LP | $26,673,916 | 1,673,395 | 45.11% | Shares |
| Kynam Capital Management, LP | $8,495,733 | 532,982 | 14.37% | Shares |
| Waterfront Wealth Inc. | $3,183,561 | 213,949 | 5.38% | Shares |
| Brooklands Fund Management Ltd | $2,741,449 | 177,325 | 4.64% | Shares |
| Eversept Partners, LP | $2,316,018 | 145,296 | 3.92% | Shares |
| MILLENNIUM MANAGEMENT LLC | $1,845,980 | 115,808 | 3.12% | Shares |
| TWO SIGMA INVESTMENTS, LP | $1,602,145 | 100,511 | 2.71% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $1,144,699 | 71,813 | 1.94% | Shares |
| CITADEL ADVISORS LLC | $971,671 | 60,958 | 1.64% | Shares |
| LCM Capital Management Inc | $818,710 | 51,362 | 1.38% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $771,002 | 48,369 | 1.30% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $765,120 | 48,000 | 1.29% | Call option |
| George Kaiser Family Foundation | $593,080 | 37,207 | 1.00% | Shares |
| JANE STREET GROUP, LLC | $523,294 | 32,829 | 0.89% | Shares |
| TWO SIGMA ADVISERS, LP | $516,265 | 36,995 | 0.87% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $462,276 | 29,001 | 0.78% | Shares |
| STATE STREET CORP | $398,755 | 25,016 | 0.67% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $385,748 | 24,200 | 0.65% | Put option |
| Bleakley Financial Group, LLC | $374,670 | 23,505 | 0.63% | Shares |
| State of New Jersey Common Pension Fund D | $300,931 | 18,879 | 0.51% | Shares |
| CITADEL ADVISORS LLC | $299,672 | 18,800 | 0.51% | Put option |
| COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS | $292,818 | 18,370 | 0.50% | Shares |
| R Squared Ltd | $269,992 | 16,938 | 0.46% | Shares |
| State of Tennessee, Department of Treasury | $239,164 | 15,004 | 0.40% | Shares |
| MORGAN STANLEY | $237,618 | 14,907 | 0.40% | Shares |
| Quadrature Capital Ltd | $236,581 | 14,842 | 0.40% | Shares |
| Quinn Opportunity Partners LLC | $228,022 | 14,305 | 0.39% | Shares |
| Cubist Systematic Strategies, LLC | $224,390 | 13,699 | 0.38% | Shares |
| EntryPoint Capital, LLC | $194,882 | 12,226 | 0.33% | Shares |
| Jump Financial, LLC | $191,407 | 12,008 | 0.32% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $187,629 | 11,771 | 0.32% | Shares |
| WELLS FARGO & COMPANY/MN | $179,564 | 11,265 | 0.30% | Shares |
| NJ State Employees Deferred Compensation Plan | $178,542 | 10,900 | 0.30% | Shares |
| Verdad Advisers, LP | $166,270 | 10,431 | 0.28% | Shares |
| CITADEL ADVISORS LLC | $164,182 | 10,300 | 0.28% | Call option |
| Steward Partners Investment Advisory, LLC | $142,025 | 8,910 | 0.24% | Shares |
| NEW YORK STATE COMMON RETIREMENT FUND | $121,224 | 7,605 | 0.21% | Shares |
| OSAIC HOLDINGS, INC. | $104,537 | 6,559 | 0.18% | Shares |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | $92,038 | 5,774 | 0.16% | Shares |
| MERCER GLOBAL ADVISORS INC /ADV | $80,099 | 5,025 | 0.14% | Shares |
| UBS Group AG | $67,171 | 4,214 | 0.11% | Shares |
| RHUMBLINE ADVISERS | $59,498 | 3,733 | 0.10% | Shares |
| NATIONAL BANK OF CANADA /FI/ | $40,137 | 2,518 | 0.07% | Shares |
| AMERIPRISE FINANCIAL INC | $30,318 | 1,902 | 0.05% | Shares |
| ROYAL BANK OF CANADA | $28,000 | 1,787 | 0.05% | Shares |
| GAMMA Investing LLC | $25,121 | 1,576 | 0.04% | Shares |
| RAYMOND JAMES FINANCIAL INC | $22,332 | 1,401 | 0.04% | Shares |
| NewEdge Advisors, LLC | $21,471 | 1,347 | 0.04% | Shares |
| Farther Finance Advisors, LLC | $15,271 | 958 | 0.03% | Shares |
| BlackRock, Inc. | $13,677 | 858 | 0.02% | Shares |
| IFP Advisors, Inc | $12,975 | 814 | 0.02% | Shares |
| Beaird Harris Wealth Management, LLC | $11,955 | 750 | 0.02% | Shares |
| ACADIAN ASSET MANAGEMENT LLC | $11,467 | 720,984 | 0.02% | Shares |
| CoreCap Advisors, LLC | $8,528 | 535 | 0.01% | Shares |
| Integrated Wealth Concepts LLC | $8,449 | 530 | 0.01% | Shares |
| JONES FINANCIAL COMPANIES LLLP | $7,844 | 493 | 0.01% | Shares |
| BARCLAYS PLC | $4,862 | 305 | 0.01% | Shares |
| JPMORGAN CHASE & CO | $3,853 | 242 | 0.01% | Shares |
| CWM, LLC | $3,644 | 252 | 0.01% | Shares |
| Westside Investment Management, Inc. | $3,268 | 205 | 0.01% | Shares |
| Global Retirement Partners, LLC | $2,646 | 166 | 0.00% | Shares |
| GROUP ONE TRADING LLC | $2,072 | 130 | 0.00% | Shares |
| HARBOUR INVESTMENTS, INC. | $1,562 | 98 | 0.00% | Shares |
| Federation des caisses Desjardins du Quebec | $1,435 | 90 | 0.00% | Shares |
| Activest Wealth Management | $797 | 50 | 0.00% | Shares |
| HighMark Wealth Management LLC | $797 | 50 | 0.00% | Shares |
| Arax Advisory Partners | $685 | 43 | 0.00% | Shares |
| Darwin Wealth Management, LLC | $398 | 25 | 0.00% | Shares |
| Continuum Advisory, LLC | $303 | 19 | 0.00% | Shares |
| Caitong International Asset Management Co., Ltd | $271 | 17 | 0.00% | Shares |
| SEI INVESTMENTS CO | $260 | 16 | 0.00% | Shares |
| Hayek Kallen Investment Management | $204 | 12,809 | 0.00% | Shares |
| Atlantic Union Bankshares Corp | $192 | 12 | 0.00% | Shares |
| Truvestments Capital LLC | $191 | 12 | 0.00% | Shares |
| Parallel Advisors, LLC | $159 | 10 | 0.00% | Shares |
| Creative Capital Management Investments LLC | $143 | 9 | 0.00% | Shares |
| Key Financial Inc | $128 | 8 | 0.00% | Shares |
| CITIGROUP INC | $128 | 8 | 0.00% | Shares |
| MCGUIRE CAPITAL ADVISORS INC | $112 | 7 | 0.00% | Shares |
| EASTERN BANK | $112 | 7 | 0.00% | Shares |
| Lindbrook Capital, LLC | $90 | 200 | 0.00% | Shares |
| Oakmont Advisory Group, LLC | $80 | 5 | 0.00% | Shares |
| Allworth Financial LP | $80 | 5 | 0.00% | Shares |
| Crewe Advisors LLC | $80 | 5 | 0.00% | Shares |
| BFSG, LLC | $80 | 5 | 0.00% | Shares |
| SBI Securities Co., Ltd. | $80 | 5 | 0.00% | Shares |
| WHITTIER TRUST CO | $63 | 4 | 0.00% | Shares |
| Caitlin John, LLC | $32 | 2 | 0.00% | Shares |
| WHITTIER TRUST CO OF NEVADA INC | $15 | 1 | 0.00% | Shares |
| JFS WEALTH ADVISORS, LLC | $15 | 1 | 0.00% | Shares |
Company insiders 37 insiders · 17 officers · 22 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Aaron Berg | President and CEO | June 26, 2026 M | 85,648 | 0 | 0 | $0 |
| Patrick Holt | President and CEO | Jan. 22, 2024 P | 314,426 | 0 | 0 | $0 |
| Karim Mikhail | President and CEO | Feb. 21, 2023 A | 283,507 | 0 | 0 | $0 |
| John F Thero | President and CEO | Nov. 19, 2019 S | 2,342,285 | 0 | 0 | $0 |
| Peter L. Fishman | SVP, CFO | Aug. 1, 2026 A | 7,619 | 0 | 0 | $0 |
| Thomas Charles Reilly | EVP and CFO | July 1, 2024 M | 94,305 | 0 | 0 | $0 |
| Michael Wayne Kalb | SVP and CFO | Dec. 16, 2019 M | 21,552 | 0 | 0 | $0 |
| David Paul Keenan | EVP, Chief Operating Officer | July 1, 2026 A | 13,470 | 0 | 0 | $0 |
| Jonathan Provoost | EVP, Chief Legal Officer | July 1, 2026 A | 4,624 | 0 | 0 | $0 |
| Steven B Ketchum | EVP, Chief Scientific Officer | July 1, 2026 A | 42,680 | 0 | 0 | $0 |
| Joseph T Kennedy | General Counsel | Oct. 7, 2019 F | 125,723 | 0 | 0 | $0 |
| Mark Salyer | Chief Commercial Officer | Feb. 1, 2018 A | — | 0 | 0 | $0 |
| Michael James Farrell | VP, Finance | Feb. 1, 2016 A | 30,190 | 0 | 0 | $0 |
| Paul Huff | Chief Commercial Officer | July 26, 2012 A | 0 | 0 | 0 | $0 |
| Stuart D Sedlack | Senior Vice President | July 26, 2012 A | 0 | 0 | 0 | $0 |
| Paresh Soni | SVP and Head of Development | Feb. 1, 2012 A | 0 | 0 | 0 | $0 |
| Frederick W Ahlholm | Vice President Finance | Feb. 1, 2012 A | 0 | 0 | 0 | $0 |
| Oliver O'Connor | Director | April 18, 2026 M | 801 | 0 | 0 | $0 |
| Paul Cohen | Director | April 18, 2026 M | 836 | 0 | 0 | $0 |
| Diane E. Sullivan | Director | April 18, 2026 M | 836 | 0 | 0 | $0 |
| Louis Sterling III | Director | April 18, 2026 M | 4,049 | 0 | 0 | $0 |
| Patrice Eadon Bonfiglio | Director | April 18, 2026 M | 836 | 0 | 0 | $0 |
| Keith Horn | Director | April 18, 2026 M | 836 | 0 | 0 | $0 |
| Odysseas D Kostas | Director | April 18, 2026 M | 836 | 0 | 0 | $0 |
| Mark Dipaolo | Director | April 18, 2025 M | 401 | 0 | 0 | $0 |
| Olsen Per Wold | Director | Jan. 10, 2023 M | 171,027 | 0 | 0 | $0 |
| David M Stack | Director | June 4, 2021 P | 40,000 | 0 | 0 | $0 |
| Joseph S Zakrzewski | Director | Jan. 3, 2020 M | 84,547 | 0 | 0 | $0 |
| Lars Ekman | Director | Nov. 12, 2019 M | 0 | 0 | 0 | $0 |
| Kristine Peterson | Director | May 20, 2019 A | 0 | 0 | 0 | $0 |
| Patrick J O'Sullivan | Director | May 20, 2019 A | — | 0 | 0 | $0 |
| VAN HEEK G JAN | Director | May 20, 2019 A | 14,168 | 0 | 0 | $0 |
| Dr. James I. Healy | Director | July 11, 2016 A | 90,000 | 0 | 0 | $0 |
| GORDON CARL L | Director | Sept. 4, 2012 S | 5,700 | 0 | 0 | $0 |
| Joseph Anderson | Director | July 10, 2012 A | 11,683 | 0 | 0 | $0 |
| David W Feigal Jr | Director | July 12, 2011 A | — | 0 | 0 | $0 |
| Abingworth LLP | 10% owner | April 19, 2012 S | 1,599,168 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 34 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Sarissa Capital Management LP, Alexander J Denner ×3 filings | March 25, 2025 | 8.08% | Amendment | Board campaign | SEC |
| Feb. 28, 2023 | — | Initial filing | — | SEC | |
| Feb. 27, 2023 | — | Initial filing | — | SEC | |
| Feb. 21, 2023 | — | Initial filing | — | SEC | |
| OR ×6 filings | Feb. 15, 2023 | — | Initial filing | — | SEC |
| Feb. 14, 2023 | — | Initial filing | — | SEC | |
| Feb. 10, 2023 | — | Initial filing | — | SEC | |
| Jan. 19, 2023 | — | Initial filing | — | SEC | |
| June 16, 2022 | — | Initial filing | — | SEC | |
| Sofinnova Venture Partners VII, L.P. (“SVP VII”), Sofinnova Management VII, L.L.C. (“SM VII”), Dr. Michael F. Powell (“Powell”), Dr. James I. Healy (“Healy”), Eric P. Buatois (“Buatois”) ×4 filings | Aug. 23, 2013 | — | Initial filing | Passive investment | SEC |
| Abingworth LLP 98-051-8585, Abingworth Bioventures V Co-Invest Growth Equity Fund LP 98-057-9772, Abingworth Bioventures V L.P. 98-051-8587, Abingworth Bioequities Master Fund Limited 66-066-0960 ×10 filings | July 22, 2013 | — | Initial filing | Board campaign | SEC |
| Boxer Capital, LLC, Boxer Asset Management Inc., Joseph Lewis ×4 filings | Aug. 24, 2011 | — | Initial filing | — | SEC |
| OrbiMed Advisors LLC, OrbiMed Capital GP III LLC, Samuel D. Isaly ×14 filings | April 28, 2011 | — | Initial filing | — | SEC |
| Fountain Healthcare Partners Fund 1, L.P. (“ Fountain ”), Fountain Healthcare Partners Ltd., Manus Rogan, Aidan King, Ena Prosser, Justin Lynch ×2 filings | Dec. 10, 2010 | — | Initial filing | — | SEC |
| Longitude Capital Partners, LLC (2), Longitude Venture Partners, L.P. (2), Longitude Capital Associates, L.P. (2), Patrick G. Enright (2), Juliet Tammenoms Bakker (2) | Oct. 26, 2010 | — | Initial filing | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.